Gemcitabine Alone or Combined with Cisplatin in Relapsed or Refractory Multiple Myeloma

• Published in: Leukemia & lymphoma Vol. 43; no. 6; pp. 1273 - 1280
• Main Authors: Offidani, M., Mele, A., Corvatta, L., Marconi, M., Malerba, L., Olivieri, A., Rupoli, S., Alesiani, F., Leoni, P.
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 2002; Taylor & Francis
• Subjects: Aged; Antimetabolites, Antineoplastic - adverse effects; Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cisplatin - administration & dosage; Cisplatin - adverse effects; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases - chemically induced; Gemcitabine; Gemcitabine And Cisplatinum; Heart Diseases - chemically induced; Hematologic Diseases - chemically induced; Humans; Life Tables; Male; Middle Aged; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; Neoplasm Recurrence, Local; Refractory Myeloma; Relapsed Myeloma; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome

Gemcitabine is a pyrimidine nucleoside analog with antitumor activity against solid tumor malignancies and leukemia. We evaluated its activity as a single agent and combining it with cisplatin in relapsed-refractory multiple myeloma (MM). Sixteen patients with advanced MM received intravenous gemcit...